Ikarian Capital, LLC Oncternal Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.7 - $1.56 $147,127 - $327,883	-210,182 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.37 - $2.43 $15,072 - $26,734	11,002 Added 5.52%	210,182 $292,000
Q3 2021 Nov 15, 2021	SELL	$3.37 - $4.76 $3,450 - $4,874	-1,024 Reduced 0.51%	199,180 $830,000
Q2 2021 Aug 16, 2021	SELL	$4.75 - $9.39 $1.24 Million - $2.44 Million	-260,119 Reduced 56.51%	200,204 $950,000
Q1 2021 May 17, 2021	SELL	$4.59 - $9.04 $2.62 Million - $5.15 Million	-570,000 Reduced 55.32%	460,323 $3.83 Million
Q4 2020 Feb 12, 2021	BUY	$1.51 - $6.3 $1.56 Million - $6.49 Million	1,030,323 New	1,030,323 $5.05 Million

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.